vs

Side-by-side financial comparison of Mistras Group, Inc. (MG) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

Mistras Group, Inc. is the larger business by last-quarter revenue ($181.5M vs $127.1M, roughly 1.4× Zai Lab Ltd). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs 5.1%). Mistras Group, Inc. produced more free cash flow last quarter ($26.0M vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs -0.8%).

Mistras Group, Inc. is a global provider of asset integrity and protection solutions, offering non-destructive testing, inspection, real-time monitoring, and engineering consulting services. Its key client segments include oil and gas, aerospace, power generation, and manufacturing industries, with operations spanning North America, Europe, and Asia-Pacific, helping clients enhance operational safety, extend asset lifespans, and minimize unplanned downtime.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

MG vs ZLAB — Head-to-Head

Bigger by revenue
MG
MG
1.4× larger
MG
$181.5M
$127.1M
ZLAB
Growing faster (revenue YoY)
ZLAB
ZLAB
+12.1% gap
ZLAB
17.1%
5.1%
MG
More free cash flow
MG
MG
$52.7M more FCF
MG
$26.0M
$-26.7M
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
-0.8%
MG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MG
MG
ZLAB
ZLAB
Revenue
$181.5M
$127.1M
Net Profit
$3.8M
Gross Margin
28.4%
51.0%
Operating Margin
7.0%
-54.6%
Net Margin
2.1%
Revenue YoY
5.1%
17.1%
Net Profit YoY
-27.4%
EPS (diluted)
$0.12
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MG
MG
ZLAB
ZLAB
Q4 25
$181.5M
$127.1M
Q3 25
$195.5M
$115.4M
Q2 25
$185.4M
$109.1M
Q1 25
$161.6M
$105.7M
Q4 24
$172.7M
$108.5M
Q3 24
$182.7M
$101.8M
Q2 24
$189.8M
$100.1M
Q1 24
$184.4M
$87.1M
Net Profit
MG
MG
ZLAB
ZLAB
Q4 25
$3.8M
Q3 25
$13.1M
$-36.0M
Q2 25
$3.0M
$-40.7M
Q1 25
$-3.2M
$-48.4M
Q4 24
$5.2M
Q3 24
$6.4M
$-41.7M
Q2 24
$6.4M
$-80.3M
Q1 24
$995.0K
$-53.5M
Gross Margin
MG
MG
ZLAB
ZLAB
Q4 25
28.4%
51.0%
Q3 25
29.8%
59.5%
Q2 25
29.1%
60.6%
Q1 25
25.3%
63.6%
Q4 24
26.5%
61.5%
Q3 24
26.8%
64.1%
Q2 24
27.1%
64.9%
Q1 24
25.0%
61.4%
Operating Margin
MG
MG
ZLAB
ZLAB
Q4 25
7.0%
-54.6%
Q3 25
10.4%
-42.3%
Q2 25
4.5%
-50.3%
Q1 25
-0.6%
-53.3%
Q4 24
6.1%
-62.6%
Q3 24
6.5%
-66.6%
Q2 24
6.3%
-76.0%
Q1 24
3.0%
-80.7%
Net Margin
MG
MG
ZLAB
ZLAB
Q4 25
2.1%
Q3 25
6.7%
-31.2%
Q2 25
1.6%
-37.3%
Q1 25
-2.0%
-45.8%
Q4 24
3.0%
Q3 24
3.5%
-40.9%
Q2 24
3.4%
-80.2%
Q1 24
0.5%
-61.4%
EPS (diluted)
MG
MG
ZLAB
ZLAB
Q4 25
$0.12
$-0.05
Q3 25
$0.41
$-0.03
Q2 25
$0.10
$-0.04
Q1 25
$-0.10
$-0.04
Q4 24
$0.17
$-0.09
Q3 24
$0.20
$-0.04
Q2 24
$0.20
$-0.08
Q1 24
$0.03
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MG
MG
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$28.0M
$689.6M
Total DebtLower is stronger
$178.0M
Stockholders' EquityBook value
$235.1M
$715.5M
Total Assets
$578.8M
$1.2B
Debt / EquityLower = less leverage
0.76×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MG
MG
ZLAB
ZLAB
Q4 25
$28.0M
$689.6M
Q3 25
$27.8M
$717.2M
Q2 25
$20.0M
$732.2M
Q1 25
$18.5M
$757.3M
Q4 24
$18.3M
$779.7M
Q3 24
$20.4M
$616.1M
Q2 24
$17.2M
$630.0M
Q1 24
$16.9M
$650.8M
Total Debt
MG
MG
ZLAB
ZLAB
Q4 25
$178.0M
Q3 25
$202.3M
Q2 25
$189.4M
Q1 25
$171.9M
Q4 24
$169.6M
Q3 24
$189.7M
Q2 24
$199.7M
Q1 24
$198.4M
Stockholders' Equity
MG
MG
ZLAB
ZLAB
Q4 25
$235.1M
$715.5M
Q3 25
$227.4M
$759.9M
Q2 25
$215.8M
$791.7M
Q1 25
$198.7M
$810.8M
Q4 24
$198.6M
$840.9M
Q3 24
$205.2M
$667.7M
Q2 24
$193.2M
$704.2M
Q1 24
$187.1M
$762.2M
Total Assets
MG
MG
ZLAB
ZLAB
Q4 25
$578.8M
$1.2B
Q3 25
$596.3M
$1.2B
Q2 25
$571.0M
$1.2B
Q1 25
$526.8M
$1.2B
Q4 24
$523.0M
$1.2B
Q3 24
$551.7M
$985.3M
Q2 24
$548.1M
$987.4M
Q1 24
$542.1M
$988.4M
Debt / Equity
MG
MG
ZLAB
ZLAB
Q4 25
0.76×
Q3 25
0.89×
Q2 25
0.88×
Q1 25
0.87×
Q4 24
0.85×
Q3 24
0.92×
Q2 24
1.03×
Q1 24
1.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MG
MG
ZLAB
ZLAB
Operating Cash FlowLast quarter
$32.1M
$-26.0M
Free Cash FlowOCF − Capex
$26.0M
$-26.7M
FCF MarginFCF / Revenue
14.3%
-21.0%
Capex IntensityCapex / Revenue
3.4%
0.5%
Cash ConversionOCF / Net Profit
8.55×
TTM Free Cash FlowTrailing 4 quarters
$8.3M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MG
MG
ZLAB
ZLAB
Q4 25
$32.1M
$-26.0M
Q3 25
$4.5M
$-32.0M
Q2 25
$-9.3M
$-31.0M
Q1 25
$5.6M
$-61.7M
Q4 24
$25.7M
$-55.8M
Q3 24
$19.4M
$-26.8M
Q2 24
$4.5M
$-42.2M
Q1 24
$604.0K
$-90.1M
Free Cash Flow
MG
MG
ZLAB
ZLAB
Q4 25
$26.0M
$-26.7M
Q3 25
$-4.1M
$-35.0M
Q2 25
$-14.7M
$-33.9M
Q1 25
$1.1M
$-63.2M
Q4 24
$22.1M
$-58.4M
Q3 24
$14.6M
$-28.2M
Q2 24
$-284.0K
$-42.9M
Q1 24
$-4.2M
$-91.1M
FCF Margin
MG
MG
ZLAB
ZLAB
Q4 25
14.3%
-21.0%
Q3 25
-2.1%
-30.4%
Q2 25
-7.9%
-31.1%
Q1 25
0.7%
-59.9%
Q4 24
12.8%
-53.8%
Q3 24
8.0%
-27.7%
Q2 24
-0.1%
-42.9%
Q1 24
-2.3%
-104.5%
Capex Intensity
MG
MG
ZLAB
ZLAB
Q4 25
3.4%
0.5%
Q3 25
4.4%
2.6%
Q2 25
2.9%
2.6%
Q1 25
2.8%
1.5%
Q4 24
2.1%
2.4%
Q3 24
2.6%
1.3%
Q2 24
2.5%
0.7%
Q1 24
2.6%
1.1%
Cash Conversion
MG
MG
ZLAB
ZLAB
Q4 25
8.55×
Q3 25
0.34×
Q2 25
-3.07×
Q1 25
Q4 24
4.96×
Q3 24
3.02×
Q2 24
0.71×
Q1 24
0.61×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MG
MG

Segment breakdown not available.

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons